{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-022617","form_type":"8-K","ticker":"OGN","cik":"0001821825","company_name":"Organon & Co.","filed_at":"2023-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.795890+00:00","generated_at":"2026-06-19T09:42:45.274443+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Organon reports FY 2022 revenue $6.2B (-2% as-reported); Q4 GAAP EPS $0.42, provides 2023 guidance","bullets":["FY 2022 revenue $6.174B, down 2% as-reported, up 4% ex-FX; diluted GAAP EPS $3.59, non-GAAP adjusted $5.03.","Q4 2022 revenue $1.485B, down 7% as-reported, up 1% ex-FX; GAAP EPS $0.42, non-GAAP adjusted $0.81.","All three franchises grew on constant-currency basis in FY 2022; Nexplanon up 11% ex-FX, Biosimilars up 17% ex-FX.","Q4 included $36M inventory charges and $8M sales return reserve due to Heist facility market action.","2023 guidance: revenue $6.15B-$6.45B; Adjusted EBITDA margin 31%-33%; quarterly dividend $0.28/share declared."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-022617","json":"https://secwatch.observer/filing/0001104659-23-022617.json","markdown":"https://secwatch.observer/filing/0001104659-23-022617.md","text":"https://secwatch.observer/filing/0001104659-23-022617.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821825/000110465923022617/0001104659-23-022617-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821825/000110465923022617/tm234187d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T09:42:45.274443+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eef206038008ac14ba47b0974261ba8e39e519ba","claim":"Organon & Co. reported the fourth quarter and full year ended December 31, 2022 results: revenue $1,485 million, net income $108 million, EPS $0.42 per diluted share.","evidence_excerpt":"For the fourth quarter of 2022, total revenue was $1,485 million, a decrease of 7% as-reported and an increase of 1% excluding the impact of foreign currency (ex-FX), compared with the fourth quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821825/000110465923022617/0001104659-23-022617-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Revenue","value":"$1,485 million"},{"label":"Net income","value":"$108 million"},{"label":"EPS","value":"$0.42 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}